Literature DB >> 16960810

Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p.

Min Ae Lee-Kirsch1, Maolian Gong, Herbert Schulz, Franz Rüschendorf, Annette Stein, Christiane Pfeiffer, Annalisa Ballarini, Manfred Gahr, Norbert Hubner, Maja Linné.   

Abstract

Systemic lupus erythematosus is a prototypic autoimmune disease. Apart from rare monogenic deficiencies of complement factors, where lupuslike disease may occur in association with other autoimmune diseases or high susceptibility to bacterial infections, its etiology is multifactorial in nature. Cutaneous findings are a hallmark of the disease and manifest either alone or in association with internal-organ disease. We describe a novel genodermatosis characterized by painful bluish-red inflammatory papular or nodular lesions in acral locations such as fingers, toes, nose, cheeks, and ears. The lesions sometimes appear plaquelike and tend to ulcerate. Manifestation usually begins in early childhood and is precipitated by cold and wet exposure. Apart from arthralgias, there is no evidence for internal-organ disease or an increased susceptibility to infection. Histological findings include a deep inflammatory infiltrate with perivascular distribution and granular deposits of immunoglobulins and complement along the basement membrane. Some affected individuals show antinuclear antibodies or immune complex formation, whereas cryoglobulins or cold agglutinins are absent. Thus, the findings are consistent with chilblain lupus, a rare form of cutaneous lupus erythematosus. Investigation of a large German kindred with 18 affected members suggests a highly penetrant trait with autosomal dominant inheritance. By single-nucleotide-polymorphism-based genomewide linkage analysis, the locus was mapped to chromosome 3p. Haplotype analysis defined the locus to a 13.8-cM interval with a LOD score of 5.04. This is the first description of a monogenic form of cutaneous lupus erythematosus. Identification of the gene responsible for familial chilblain lupus may shed light on the pathogenesis of common forms of connective-tissue disease such as systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960810      PMCID: PMC1592563          DOI: 10.1086/507848

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  35 in total

1.  GRR: graphical representation of relationship errors.

Authors:  G R Abecasis; S S Cherny; W O Cookson; L R Cardon
Journal:  Bioinformatics       Date:  2001-08       Impact factor: 6.937

2.  Merlin--rapid analysis of dense genetic maps using sparse gene flow trees.

Authors:  Gonçalo R Abecasis; Stacey S Cherny; William O Cookson; Lon R Cardon
Journal:  Nat Genet       Date:  2001-12-03       Impact factor: 38.330

3.  Systemic lupus erythematosus or Aicardi-Goutières syndrome?

Authors:  J Aicardi; F Goutières
Journal:  Neuropediatrics       Date:  2000-06       Impact factor: 1.947

4.  Molecular basis of a selective C1s deficiency associated with early onset multiple autoimmune diseases.

Authors:  M A Dragon-Durey; P Quartier; V Frémeaux-Bacchi; J Blouin; C de Barace; A M Prieur; L Weiss; W H Fridman
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

5.  Childhood pernio and cryoproteins.

Authors:  W L Weston; J G Morelli
Journal:  Pediatr Dermatol       Date:  2000 Mar-Apr       Impact factor: 1.588

6.  Familial systemic lupus erythematosus and congenital infection-like syndrome.

Authors:  R C Dale; S P Tang; J Z Heckmatt; F M Tatnall
Journal:  Neuropediatrics       Date:  2000-06       Impact factor: 1.947

7.  Increased interleukin-17 production in patients with systemic sclerosis.

Authors:  K Kurasawa; K Hirose; H Sano; H Endo; H Shinkai; Y Nawata; K Takabayashi; I Iwamoto
Journal:  Arthritis Rheum       Date:  2000-11

8.  Protein kinase Cdelta controls self-antigen-induced B-cell tolerance.

Authors:  Ingrid Mecklenbräuker; Kaoru Saijo; Nai-Ying Zheng; Michael Leitges; Alexander Tarakhovsky
Journal:  Nature       Date:  2002-04-25       Impact factor: 49.962

9.  Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta.

Authors:  Akimoto Miyamoto; Keiko Nakayama; Hiroyuki Imaki; Sachiko Hirose; Yi Jiang; Masaaki Abe; Tadasuke Tsukiyama; Hiroyasu Nagahama; Shigeo Ohno; Shigetsugu Hatakeyama; Keiichi I Nakayama
Journal:  Nature       Date:  2002-04-25       Impact factor: 49.962

10.  A second locus for Aicardi-Goutieres syndrome at chromosome 13q14-21.

Authors:  M Ali; L J Highet; D Lacombe; C Goizet; M D King; U Tacke; M S van der Knaap; L Lagae; C Rittey; H G Brunner; H van Bokhoven; B Hamel; Y A Oade; A Sanchis; I Desguerre; D Cau; N Mathieu; M L Moutard; P Lebon; D Kumar; A P Jackson; Y J Crow
Journal:  J Med Genet       Date:  2005-05-20       Impact factor: 6.318

View more
  43 in total

Review 1.  [Type I interferonopathies. Systemic inflammatory diseases triggered by type I interferons].

Authors:  C Günther; F Schmidt; N König; M A Lee-Kirsch
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

2.  A TREX1 mutation causing cerebral vasculopathy in a patient with familial chilblain lupus.

Authors:  Kazuo Yamashiro; Ryota Tanaka; Yuanzhe Li; Michitaka Mikasa; Nobutaka Hattori
Journal:  J Neurol       Date:  2013-08-30       Impact factor: 4.849

3.  Deregulated type I IFN response in TREX1-associated familial chilblain lupus.

Authors:  Katrin Peschke; Franziska Friebe; Nick Zimmermann; Tom Wahlicht; Tina Schumann; Martin Achleitner; Nicole Berndt; Hella Luksch; Rayk Behrendt; Min Ae Lee-Kirsch; Axel Roers; Claudia Günther
Journal:  J Invest Dermatol       Date:  2013-11-22       Impact factor: 8.551

4.  The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease.

Authors:  Duane A Lehtinen; Scott Harvey; Matthew J Mulcahy; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

5.  Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease.

Authors:  Jessica L Grieves; Jason M Fye; Scott Harvey; Jason M Grayson; Thomas Hollis; Fred W Perrino
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

6.  Aicardi-Goutières syndrome protein TREX1 suppresses L1 and maintains genome integrity through exonuclease-independent ORF1p depletion.

Authors:  Peng Li; Juan Du; John L Goodier; Jingwei Hou; Jian Kang; Haig H Kazazian; Ke Zhao; Xiao-Fang Yu
Journal:  Nucleic Acids Res       Date:  2017-05-05       Impact factor: 16.971

Review 7.  [Familial chilblain lupus : Type 1 interferonopathy with model character].

Authors:  C Fiehn
Journal:  Z Rheumatol       Date:  2017-05       Impact factor: 1.372

8.  Activated STING in a vascular and pulmonary syndrome.

Authors:  Y Liu; A A Jesus; B Marrero; Z Deng; M Boehm; A S Paller; D Yang; S E Ramsey; G A Montealegre Sanchez; K Tenbrock; H Wittkowski; O Y Jones; H S Kuehn; C-C R Lee; M A DiMattia; E W Cowen; B Gonzalez; I Palmer; J J DiGiovanna; A Biancotto; H Kim; W L Tsai; A M Trier; Y Huang; D L Stone; S Hill; H J Kim; C St Hilaire; S Gurprasad; N Plass; D Chapelle; I Horkayne-Szakaly; D Foell; A Barysenka; F Candotti; S M Holland; J D Hughes; H Mehmet; A C Issekutz; M Raffeld; J McElwee; J R Fontana; C P Minniti; S Moir; D L Kastner; M Gadina; A C Steven; P T Wingfield; S R Brooks; S D Rosenzweig; T A Fleisher; R Goldbach-Mansky
Journal:  N Engl J Med       Date:  2014-07-16       Impact factor: 91.245

Review 9.  Mouse models for Aicardi-Goutières syndrome provide clues to the molecular pathogenesis of systemic autoimmunity.

Authors:  R Behrendt; A Roers
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

Review 10.  New roles for the major human 3'-5' exonuclease TREX1 in human disease.

Authors:  David Kavanagh; Dirk Spitzer; Parul H Kothari; Aisha Shaikh; M Kathryn Liszewski; Anna Richards; John P Atkinson
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.